Wild, C. and Patera, N. and Küllinger, R. and Narath, M. (2015): PET/PET-CT Evidence for need based planning (in oncology indications). HTA-Projektbericht 77.
|PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader|
In nearly all Western countries, HTA-reports on Positron Emission Tomography/PET imaging have been written in the last two decades. 155 only in the last 10 years (!). Hardly any other medical technology has undergone so many evaluations. This large abundance is ultimately an expression of an unfading uncertainty about the value of PET imaging in patient care. The (Austrian) HTA report presented here has the intention of supplying decision support for evidence- and needs-based PET device planning.
Since PET units are almost exclusively utilised for oncology patients, the report confines itself to statements on evidence in oncological indications: Results from 35 HTAs and recommendations of 7 (4 nuclear medicine, 2 oncological and 1 radiological) societies were taken into account. In a comparison of results on oncological indications from HTAs and from the recommendations of medical societies, it appears that there is general agreement on „confirmed” indications; the significant differences lie in the level of detail of the partial (sub-) indications and in the conditions regarding access and graded pre-diagnostics.
The great uncertainty about PET imaging also becomes apparent in international planning documents and in reimbursement decisions: Equipment density alone has little significance; information on the utilisation of the equipment, however, shows a high variability (from 1,000 in Scandinavia to 2,400 in Italy). For planning purposes, 2,000 patients per device and year are generally assumed.
In North America, reimbursement institutions have made – based on PET register-studies and pragmatic clinical studies on the role of PET imaging in oncological indications – (highly differing) decisions in recent years: In the USA, the CMS/Center for Medicare & Medicaid Services drastically expanded the reimbursement spectrum; in Ontario/Canada it was narrowed down to 7 indications at the same time. In Germany, 8 benefit assessments on oncological PET indications have been conducted thus far and 3 clinical „trial studies” are planned. Final decisions are yet to be made here. Against the backdrop of obvious political decision-making pressure, the creation of explicit indication lists (the inclusion, but also exclusion of indications) is recommended as referral and reimbursement support.
|Item Type:||Project Report|
|Keywords:||PET, Positron Emission Tomography, imaging, oncology, device planning, needs assessment|
|Subjects:||WB Practice of medicine > WB 141-293 Diagnosis|
WA Public health > WA 525-590 Health administration and organisation
WB Practice of medicine > WB 102 Evidence-based medicine
QZ Pathology > QZ 200-380 Neoplasms.Cysts
W Health professions > W 84 Health services. Quality of health care
WN Radiology. Diagnostic imaging
|Series Name:||HTA-Projektbericht 77|
|Deposited on:||12 Jan 2015 14:56|
|Last Modified:||25 Feb 2015 14:05|
Repository Staff Only: item control page